Literature DB >> 31675136

Leukocyte telomere length is reduced in patients with major depressive disorder.

Claudia Pisanu1, Evangelia Eirini Tsermpini2, Maria Skokou3, Zoe Kordou2, Philippos Gourzis4, Konstantinos Assimakopoulos4, Donatella Congiu1, Anna Meloni1, Dimitrios Balasopoulos2, George P Patrinos2,5,6, Alessio Squassina1.   

Abstract

Major depressive disorder (MDD) is a chronic, severe psychiatric illness with an incidence of 3% worldwide. MDD patients have a significantly impaired quality of life and reduced life expectancy compared to unaffected individuals, the latter being largely accounted for by an increased incidence of suicide and cardiovascular disorders. The premature mortality observed in MDD has been considered a signature of accelerated aging, a hypothesis supported by data showing altered functioning and morphology of several brain regions that are typically present in the aging population. Telomere shortening is a hallmark of cellular aging, and as such several studies explored the involvement of disrupted telomere dynamics in MDD, reporting contrasting findings. In the current study, we measured leukocyte telomere length (LTL) in a sample of 54 MDD patients and 47 non-psychiatric controls characterized for response to antidepressant treatment. After correcting for age, sex, and body mass index, we showed significantly reduced LTL in affected individuals compared to controls (beta = -.22, p = .02). There was no difference in LTL between treatment resistant or responsive MDD patients. Moreover, we observed no correlation between lifetime exposure to antidepressants and LTL. Our study showed that MDD patients have shorter telomeres compared to controls, supporting the hypothesis of accelerated aging in this disorder. However, LTL seemed not to be influenced by antidepressant treatment or to correlate with clinical response to these antidepressants. Further investigations in larger samples and possibly with longitudinal design are warranted to elucidate the role of altered telomere dynamics in MDD.
© 2019 Wiley Periodicals, Inc.

Entities:  

Keywords:  depression; leukocytes; mood disorders; telomeres

Mesh:

Substances:

Year:  2019        PMID: 31675136     DOI: 10.1002/ddr.21612

Source DB:  PubMed          Journal:  Drug Dev Res        ISSN: 0272-4391            Impact factor:   4.360


  3 in total

Review 1.  miRNAs as potential diagnostic biomarkers and pharmacogenomic indicators in psychiatric disorders.

Authors:  Evangelia Eirini Tsermpini; Christina I Kalogirou; George C Kyriakopoulos; George P Patrinos; Constantinos Stathopoulos
Journal:  Pharmacogenomics J       Date:  2022-06-20       Impact factor: 3.245

2.  Telomere attrition and inflammatory load in severe psychiatric disorders and in response to psychotropic medications.

Authors:  Alessio Squassina; Mirko Manchia; Claudia Pisanu; Raffaella Ardau; Carlo Arzedi; Alberto Bocchetta; Paola Caria; Cristina Cocco; Donatella Congiu; Eleonora Cossu; Tinuccia Dettori; Daniela Virginia Frau; Mario Garzilli; Elias Manca; Anna Meloni; Maria Antonietta Montis; Andrea Mura; Mariella Nieddu; Barbara Noli; Pasquale Paribello; Federica Pinna; Renato Robledo; Giovanni Severino; Valeria Sogos; Maria Del Zompo; Gian Luca Ferri; Caterina Chillotti; Roberta Vanni; Bernardo Carpiniello
Journal:  Neuropsychopharmacology       Date:  2020-09-12       Impact factor: 7.853

3.  Telomere and Telomerase: Biological Markers of Organic Vital Force State and Homeopathic Treatment Effectiveness.

Authors:  Marcus Zulian Teixeira
Journal:  Homeopathy       Date:  2021-05-17       Impact factor: 1.444

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.